GPT and metabolic dysfunction-associated steatotic liver disease: The ORs [95% CI] of suspected NAFLD changed across the quartiles as follows: for serum ALT, from 1.02 [0.85, 1.23] to 0.72 [0.59, 0.87]; for serum GGT, from 0.79 [0.56, 1.13] to 0.64 [0.44, 0.92]; for FLI, from 0.98 [0.67, 1.44] to 0.70 [0.48, 1.02]; and for HSI, from 0.91 [0.73, 1.14] to 0.65 [0.52, 0.81] with dose–response relationships (all p for trend < 0.01).